2l6s - Revision history

OCA at 06:53, 1 May 2024

OCA — Wed, 01 May 2024 06:53:55 GMT

←Older revision		Revision as of 06:53, 1 May 2024
Line 7:		Line 7:
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2l6s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2l6s OCA], [https://pdbe.org/2l6s PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2l6s RCSB], [https://www.ebi.ac.uk/pdbsum/2l6s PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2l6s ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2l6s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2l6s OCA], [https://pdbe.org/2l6s PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2l6s RCSB], [https://www.ebi.ac.uk/pdbsum/2l6s PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2l6s ProSAT]</span></td></tr>
	</table>		</table>
-	<div style="background-color:#fffaf0;">
-	== Publication Abstract from PubMed ==
-	To infect host cells, most enveloped viruses must insert a hydrophobic fusion peptide into the host cell membrane. Thus, fusion peptides may be valuable targets for developing drugs that block virus entry. We have shown previously that a natural 20-residue fragment of alpha(1)-antitrypsin, designated VIRus-Inhibitory Peptide (VIRIP), that binds to the gp41 fusion peptide of HIV-1 prevents the virus from entering target cells in vitro. Here, we examine the efficacy of 10-day monotherapy with the optimized VIR-576 derivative of VIRIP in treatment-naive, HIV-1-infected individuals with viral RNA loads of >/=10,000 copies per ml. We report that at the highest dose (5.0 grams per day), intravenous infusion of VIR-576 reduced the mean plasma viral load by 1.23 log(10) copies per ml without causing severe adverse effects. Our results are proof of concept that fusion peptide inhibitors suppress viral replication in human patients, and offer prospects for the development of a new class of drugs that prevent virus particles from anchoring to and infecting host cells.
-
-	Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide.,Forssmann WG, The YH, Stoll M, Adermann K, Albrecht U, Barlos K, Busmann A, Canales-Mayordomo A, Gimenez-Gallego G, Hirsch J, Jimenez-Barbero J, Meyer-Olson D, Munch J, Perez-Castells J, Standker L, Kirchhoff F, Schmidt RE Sci Transl Med. 2010 Dec 22;2(63):63re3. PMID:21178138<ref>PMID:21178138</ref>
-
-	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	</div>
-	<div class="pdbe-citations 2l6s" style="background-color:#fffaf0;"></div>
-	== References ==
-	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>

OCA at 12:11, 15 November 2023

OCA — Wed, 15 Nov 2023 12:11:54 GMT

←Older revision		Revision as of 12:11, 15 November 2023
Line 1:		Line 1:

	==Efficacy of an HIV-1 entry inhibitor targeting the GP41 fusion peptide==		==Efficacy of an HIV-1 entry inhibitor targeting the GP41 fusion peptide==
-	<StructureSection load='2l6s' size='340' side='right'caption='[[2l6s~~]], [[NMR_Ensembles_of_Models \| 14 NMR models~~]]' scene=''>	+	<StructureSection load='2l6s' size='340' side='right'caption='[[2l6s]]' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[2l6s]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2L6S OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2L6S FirstGlance]. <br>		<table><tr><td colspan='2'>[[2l6s]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2L6S OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2L6S FirstGlance]. <br>
-	</td></tr><tr id='~~related~~'><td class="sblockLbl"><b>[[~~Related_structure~~\|~~Related~~:]]</b></td><td class="sblockDat"~~><div style~~=~~'overflow: auto; max-height: 3em;'>[[2jnr\|2jnr]], [[2l6t\|2l6t]]</div~~></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">Solution NMR</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2l6s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2l6s OCA], [https://pdbe.org/2l6s PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2l6s RCSB], [https://www.ebi.ac.uk/pdbsum/2l6s PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2l6s ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2l6s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2l6s OCA], [https://pdbe.org/2l6s PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2l6s RCSB], [https://www.ebi.ac.uk/pdbsum/2l6s PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2l6s ProSAT]</span></td></tr>
	</table>		</table>
Line 21:		Line 21:
	</StructureSection>		</StructureSection>
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Adermann, K]]	+	[[Category: Adermann K]]
-	[[Category: Albrecht, U]]	+	[[Category: Albrecht U]]
-	[[Category: Barlos, K]]	+	[[Category: Barlos K]]
-	[[Category: Busmann, A]]	+	[[Category: Busmann A]]
-	[[Category: Canales-Mayordomo, A]]	+	[[Category: Canales-Mayordomo A]]
-	[[Category: Forssmann, W]]	+	[[Category: Forssmann W]]
-	[[Category: Gimenez-Gallego, G]]	+	[[Category: Gimenez-Gallego G]]
-	[[Category: Hirsch, J]]	+	[[Category: Hirsch J]]
-	[[Category: Jimenez-Barbero, J]]	+	[[Category: Jimenez-Barbero J]]
-	[[Category: Kirchhoff, F]]	+	[[Category: Kirchhoff F]]
-	[[Category: Meyer-Olson, D]]	+	[[Category: Meyer-Olson D]]
-	[[Category: Muench, J]]	+	[[Category: Muench J]]
-	[[Category: Perez-Castells, J]]	+	[[Category: Perez-Castells J]]
-	[[Category: Schmidt~~, R E~~]]	+	[[Category: Schmidt RE]]
-	[[Category: Standker, L]]	+	[[Category: Standker L]]
-	[[Category: Stoll, M]]	+	[[Category: Stoll M]]
-	[[Category: The, Y]]	+	[[Category: The Y]]
-	~~[[Category: Anti-viral polypeptide]]~~	+
-	~~[[Category: Antiviral protein~~]]	+

OCA at 07:48, 9 February 2022

OCA — Wed, 09 Feb 2022 07:48:51 GMT

←Older revision		Revision as of 07:48, 9 February 2022
Line 3:		Line 3:
	<StructureSection load='2l6s' size='340' side='right'caption='[[2l6s]], [[NMR_Ensembles_of_Models \| 14 NMR models]]' scene=''>		<StructureSection load='2l6s' size='340' side='right'caption='[[2l6s]], [[NMR_Ensembles_of_Models \| 14 NMR models]]' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[2l6s]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2L6S OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://proteopedia.org/fgij/fg.htm?mol=2L6S FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[2l6s]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2L6S OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2L6S FirstGlance]. <br>
-	</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[2jnr\|2jnr]], [[2l6t\|2l6t]]</td></tr>	+	</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[2jnr\|2jnr]], [[2l6t\|2l6t]]</div></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://proteopedia.org/fgij/fg.htm?mol=2l6s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2l6s OCA], [~~http~~://pdbe.org/2l6s PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=2l6s RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/2l6s PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=2l6s ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2l6s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2l6s OCA], [https://pdbe.org/2l6s PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2l6s RCSB], [https://www.ebi.ac.uk/pdbsum/2l6s PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2l6s ProSAT]</span></td></tr>
	</table>		</table>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">

OCA at 06:59, 6 May 2020

OCA — Wed, 06 May 2020 06:59:38 GMT

←Older revision		Revision as of 06:59, 6 May 2020
Line 1:		Line 1:

	==Efficacy of an HIV-1 entry inhibitor targeting the GP41 fusion peptide==		==Efficacy of an HIV-1 entry inhibitor targeting the GP41 fusion peptide==
-	<StructureSection load='2l6s' size='340' side='right' caption='[[2l6s]], [[NMR_Ensembles_of_Models \| 14 NMR models]]' scene=''>	+	<StructureSection load='2l6s' size='340' side='right'caption='[[2l6s]], [[NMR_Ensembles_of_Models \| 14 NMR models]]' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[2l6s]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2L6S OCA]. For a <b>guided tour on the structure components</b> use [http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=2L6S FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[2l6s]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2L6S OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=2L6S FirstGlance]. <br>
	</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[2jnr\|2jnr]], [[2l6t\|2l6t]]</td></tr>		</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[2jnr\|2jnr]], [[2l6t\|2l6t]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=2l6s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2l6s OCA], [http://pdbe.org/2l6s PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2l6s RCSB], [http://www.ebi.ac.uk/pdbsum/2l6s PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=2l6s ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=2l6s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2l6s OCA], [http://pdbe.org/2l6s PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2l6s RCSB], [http://www.ebi.ac.uk/pdbsum/2l6s PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=2l6s ProSAT]</span></td></tr>
	</table>		</table>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
Line 20:		Line 20:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Large Structures]]
	[[Category: Adermann, K]]		[[Category: Adermann, K]]
	[[Category: Albrecht, U]]		[[Category: Albrecht, U]]

OCA at 19:27, 1 August 2018

OCA — Wed, 01 Aug 2018 19:27:03 GMT

←Older revision		Revision as of 19:27, 1 August 2018
Line 1:		Line 1:
		+
	==Efficacy of an HIV-1 entry inhibitor targeting the GP41 fusion peptide==		==Efficacy of an HIV-1 entry inhibitor targeting the GP41 fusion peptide==
	<StructureSection load='2l6s' size='340' side='right' caption='[[2l6s]], [[NMR_Ensembles_of_Models \| 14 NMR models]]' scene=''>		<StructureSection load='2l6s' size='340' side='right' caption='[[2l6s]], [[NMR_Ensembles_of_Models \| 14 NMR models]]' scene=''>
Line 4:		Line 5:
	<table><tr><td colspan='2'>[[2l6s]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2L6S OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2L6S FirstGlance]. <br>		<table><tr><td colspan='2'>[[2l6s]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2L6S OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2L6S FirstGlance]. <br>
	</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[2jnr\|2jnr]], [[2l6t\|2l6t]]</td></tr>		</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[2jnr\|2jnr]], [[2l6t\|2l6t]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2l6s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2l6s OCA], [http://pdbe.org/2l6s PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2l6s RCSB], [http://www.ebi.ac.uk/pdbsum/2l6s PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2l6s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2l6s OCA], [http://pdbe.org/2l6s PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2l6s RCSB], [http://www.ebi.ac.uk/pdbsum/2l6s PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=2l6s ProSAT]</span></td></tr>
	</table>		</table>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">

OCA at 23:14, 10 September 2015

OCA — Thu, 10 Sep 2015 23:14:14 GMT

←Older revision		Revision as of 23:14, 10 September 2015
Line 4:		Line 4:
	<table><tr><td colspan='2'>[[2l6s]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2L6S OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2L6S FirstGlance]. <br>		<table><tr><td colspan='2'>[[2l6s]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2L6S OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2L6S FirstGlance]. <br>
	</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[2jnr\|2jnr]], [[2l6t\|2l6t]]</td></tr>		</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[2jnr\|2jnr]], [[2l6t\|2l6t]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2l6s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2l6s OCA], [http://www.rcsb.org/pdb/explore.do?structureId=2l6s RCSB], [http://www.ebi.ac.uk/pdbsum/2l6s PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2l6s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2l6s OCA], [http://pdbe.org/2l6s PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2l6s RCSB], [http://www.ebi.ac.uk/pdbsum/2l6s PDBsum]</span></td></tr>
	</table>		</table>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
Line 14:		Line 14:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 2l6s" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>

OCA at 09:38, 25 January 2015

OCA — Sun, 25 Jan 2015 09:38:29 GMT

←Older revision		Revision as of 09:38, 25 January 2015
Line 18:		Line 18:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: Adermann, K.]]	+	[[Category: Adermann, K]]
-	[[Category: Albrecht, U.]]	+	[[Category: Albrecht, U]]
-	[[Category: Barlos, K.]]	+	[[Category: Barlos, K]]
-	[[Category: Busmann, A.]]	+	[[Category: Busmann, A]]
-	[[Category: Canales-Mayordomo, A.]]	+	[[Category: Canales-Mayordomo, A]]
-	[[Category: Forssmann, W.]]	+	[[Category: Forssmann, W]]
-	[[Category: Gimenez-Gallego, G.]]	+	[[Category: Gimenez-Gallego, G]]
-	[[Category: Hirsch, J.]]	+	[[Category: Hirsch, J]]
-	[[Category: Jimenez-Barbero, J.]]	+	[[Category: Jimenez-Barbero, J]]
-	[[Category: Kirchhoff, F.]]	+	[[Category: Kirchhoff, F]]
-	[[Category: Meyer-Olson, D.]]	+	[[Category: Meyer-Olson, D]]
-	[[Category: Muench, J.]]	+	[[Category: Muench, J]]
-	[[Category: Perez-Castells, J.]]	+	[[Category: Perez-Castells, J]]
-	[[Category: Schmidt, R E.]]	+	[[Category: Schmidt, R E]]
-	[[Category: Standker, L.]]	+	[[Category: Standker, L]]
-	[[Category: Stoll, M.]]	+	[[Category: Stoll, M]]
-	[[Category: The, Y.]]	+	[[Category: The, Y]]
	[[Category: Anti-viral polypeptide]]		[[Category: Anti-viral polypeptide]]
	[[Category: Antiviral protein]]		[[Category: Antiviral protein]]

OCA at 09:25, 5 November 2014

OCA — Wed, 05 Nov 2014 09:25:17 GMT

←Older revision		Revision as of 09:25, 5 November 2014
Line 1:		Line 1:
-	[[~~Image:~~2l6s.~~png~~\|~~left~~\|~~200px~~]]	+	==Efficacy of an HIV-1 entry inhibitor targeting the GP41 fusion peptide==
		+	<StructureSection load='2l6s' size='340' side='right' caption='[[2l6s]], [[NMR_Ensembles_of_Models \| 14 NMR models]]' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[2l6s]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2L6S OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2L6S FirstGlance]. <br>
		+	</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[2jnr\|2jnr]], [[2l6t\|2l6t]]</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2l6s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2l6s OCA], [http://www.rcsb.org/pdb/explore.do?structureId=2l6s RCSB], [http://www.ebi.ac.uk/pdbsum/2l6s PDBsum]</span></td></tr>
		+	</table>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	To infect host cells, most enveloped viruses must insert a hydrophobic fusion peptide into the host cell membrane. Thus, fusion peptides may be valuable targets for developing drugs that block virus entry. We have shown previously that a natural 20-residue fragment of alpha(1)-antitrypsin, designated VIRus-Inhibitory Peptide (VIRIP), that binds to the gp41 fusion peptide of HIV-1 prevents the virus from entering target cells in vitro. Here, we examine the efficacy of 10-day monotherapy with the optimized VIR-576 derivative of VIRIP in treatment-naive, HIV-1-infected individuals with viral RNA loads of >/=10,000 copies per ml. We report that at the highest dose (5.0 grams per day), intravenous infusion of VIR-576 reduced the mean plasma viral load by 1.23 log(10) copies per ml without causing severe adverse effects. Our results are proof of concept that fusion peptide inhibitors suppress viral replication in human patients, and offer prospects for the development of a new class of drugs that prevent virus particles from anchoring to and infecting host cells.

-	~~{{STRUCTURE_2l6s\| PDB=2l6s \| SCENE= }}~~	+	Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide.,Forssmann WG, The YH, Stoll M, Adermann K, Albrecht U, Barlos K, Busmann A, Canales-Mayordomo A, Gimenez-Gallego G, Hirsch J, Jimenez-Barbero J, Meyer-Olson D, Munch J, Perez-Castells J, Standker L, Kirchhoff F, Schmidt RE Sci Transl Med. 2010 Dec 22;2(63):63re3. PMID:21178138<ref>PMID:21178138</ref>

-	~~===Efficacy~~ of ~~an HIV-1 entry inhibitor targeting~~ the ~~GP41 fusion peptide===~~	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-		+	</div>
-	~~{{ABSTRACT_PUBMED_21178138}}~~	+	== References ==
-		+	<references/>
-	~~==About this Structure==~~	+	__TOC__
-	~~[[2l6s]] is a 1 chain structure~~. ~~Full experimental information is available from [http://oca~~.~~weizmann~~.~~ac.il~~/~~oca-bin/ocashort?id=2L6S OCA].~~	+	</StructureSection>
-		+
-	==~~Reference~~==	+
-	<~~ref group="xtra">PMID:021178138<~~/~~ref~~><~~ref group="xtra">PMID:017448989</ref><references group="xtra"~~/>	+
	[[Category: Adermann, K.]]		[[Category: Adermann, K.]]
	[[Category: Albrecht, U.]]		[[Category: Albrecht, U.]]

OCA at 13:06, 30 January 2013

OCA — Wed, 30 Jan 2013 13:06:50 GMT

←Older revision		Revision as of 13:06, 30 January 2013
Line 1:		Line 1:
	[[Image:2l6s.png\|left\|200px]]		[[Image:2l6s.png\|left\|200px]]

-	<!--
-	The line below this paragraph, containing "STRUCTURE_2l6s", creates the "Structure Box" on the page.
-	You may change the PDB parameter (which sets the PDB file loaded into the applet)
-	or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
-	or leave the SCENE parameter empty for the default display.
-	-->
	{{STRUCTURE_2l6s\| PDB=2l6s \| SCENE= }}		{{STRUCTURE_2l6s\| PDB=2l6s \| SCENE= }}

	===Efficacy of an HIV-1 entry inhibitor targeting the GP41 fusion peptide===		===Efficacy of an HIV-1 entry inhibitor targeting the GP41 fusion peptide===

-
-	<!--
-	The line below this paragraph, {{ABSTRACT_PUBMED_21178138}}, adds the Publication Abstract to the page
-	(as it appears on PubMed at http://www.pubmed.gov), where 21178138 is the PubMed ID number.
-	-->
	{{ABSTRACT_PUBMED_21178138}}		{{ABSTRACT_PUBMED_21178138}}

Line 22:		Line 11:

	==Reference==		==Reference==
-	<ref group="xtra">PMID:~~21178138~~</ref><ref group="xtra">PMID:~~17448989~~</ref><references group="xtra"/>	+	<ref group="xtra">PMID:021178138</ref><ref group="xtra">PMID:017448989</ref><references group="xtra"/>
	[[Category: Adermann, K.]]		[[Category: Adermann, K.]]
	[[Category: Albrecht, U.]]		[[Category: Albrecht, U.]]
Line 40:		Line 29:
	[[Category: Stoll, M.]]		[[Category: Stoll, M.]]
	[[Category: The, Y.]]		[[Category: The, Y.]]
		+	[[Category: Anti-viral polypeptide]]
		+	[[Category: Antiviral protein]]

OCA at 19:53, 14 March 2011

OCA — Mon, 14 Mar 2011 19:53:31 GMT

←Older revision		Revision as of 19:53, 14 March 2011
Line 1:		Line 1:
-	[[Image:2l6s.~~jpg~~\|left\|200px]]	+	[[Image:2l6s.png\|left\|200px]]

	<!--		<!--